Leading experts in digital transformation will gather at the event to discuss how emerging technologies are reshaping the ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

Vertex Pharmaceuticals Incorporated will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will host a ...

Tourism contributed 8.6% to the Philippines' GDP in 2023, demonstrating its significance to the national economy. According to the 2023 Sustainable Travel Report, 76% of travelers prioritize ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), UnitedHealth ...

By Akin Nazli in Belgrade Enka Insaat (ENKAI) on January 15 signed a £529mn contract with Essar Energy Transition (EET) Hydrogen to build a 350-MW low-carbon plant, according to statements from the ...

Experimental particle physicist Ian Shipsey, a remarkable leader and individual, passed away suddenly and unexpectedly in ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...

Notably, Vertex Pharmaceuticals (NASDAQ: VRTX), which focuses on developing treatments for rare diseases, has significantly outpaced both its biotechnology peers and the S&P 500 since early 2022.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...